ISEE Jan 2024 35.000 call
| Previous Close | 2.7500 |
| Open | 2.9000 |
| Bid | 3.0000 |
| Ask | 7.7000 |
| Strike | 35.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 2.7500 - 2.9000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 232 |
Business WireIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J., June 02, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
ZacksAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
- Reuters
UPDATE 1-Japan's Astellas Pharma agrees to buy IVERIC Bio for $5.9 bln
Japan's Astellas Pharma said on Monday it agreed to buy U.S.-based drugmaker IVERIC Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. Through Berry Merger Sub Inc, a wholly-owned subsidiary of Astellas U.S. Holding, the Japanese company agreed to acquire IVERIC for $40 per share in cash, Astellas said in a release. The acquisition price is a 22% premium to IVERIC's $32.89 closing price on April 28.
ReutersJapan's Astellas to buy Iveric Bio for $5.9 billion to expand eyesight treatments
TOKYO (Reuters) -Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. The deal marks the fifth major overseas acquisition by Astellas, Japan's third biggest drugmaker by sales, since 2019 in a push to shore up its pipeline as its main sellers lose patent protection. It is the second-largest cross-border acquisition for a Japanese drugmaker in the past five years, according to Refinitiv data, following Takeda Pharmaceutical Co's $6 billion purchase of Nimbus Therapeutics' psoriasis drug unit announced in December.
- Business Wire
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
TOKYO & PARSIPPANY, N.J., April 30, 2023--Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per sh
Simply Wall St.When Will IVERIC bio, Inc. (NASDAQ:ISEE) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at IVERIC bio, Inc.'s...
Business WireIveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting
PARSIPPANY, N.J., April 23, 2023--Iveric Bio announced new findings from exploratory analyses of data for ACP, presented at the 2023 annual meeting of the ARVO in New Orleans.
ZacksApellis (APLS) Kindles Acquisition Interest Per Bloomberg
Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.
- Thomson Reuters StreetEvents
Q4 2022 IVERIC bio Inc Earnings Call
Q4 2022 IVERIC bio Inc Earnings Call
Motley FoolIVERIC Bio (ISEE) Q4 2022 Earnings Call Transcript
Representing IVERIC bio today are Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Keith Westby, chief operating officer; David Carroll, chief financial officer; Dr. Dhaval Desai, chief development officer; Chris Simms, chief commercial officer; and Tony Gibney, chief business and strategy officer. While we may elect to update these forward-looking statements at some point in the future, we disclaim any obligation to do so as except required by law.
Business WireIveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J., March 01, 2023--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2022 and provided a general business update.
Business WireIveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials
PARSIPPANY, N.J., March 01, 2023--Iveric Bio announced an analysis from the ACP GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment.
Business WireIveric Bio to Present at the Cowen 43rd Annual Health Care Conference
PARSIPPANY, N.J., February 28, 2023--Iveric Bio announced that the Company will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023.
Business WireIveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
PARSIPPANY, N.J., February 22, 2023--IVERIC bio today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023.
Business WireIveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
PARSIPPANY, N.J., February 16, 2023--Iveric Bio announced that the U.S. FDA completed its filing review and accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP).
- Simply Wall St.
Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8b
Last week, IVERIC bio, Inc. ( NASDAQ:ISEE ) insiders, who had purchased shares in the previous 12 months were rewarded...
Business WireIveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
PARSIPPANY, N.J., January 03, 2023--Iveric Bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023.
Business WireIveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
PARSIPPANY, N.J., December 20, 2022--Iveric Bio announced that it has submitted the third and final part of its NDA for rolling review of avacincaptad pegol (ACP) to the US FDA.
Business WireIveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
PARSIPPANY, N.J., December 01, 2022--Iveric Bio announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price of $22.50 per share.
Business WireIveric Bio Announces Proposed Offering of Common Stock
PARSIPPANY, N.J., November 30, 2022--Iveric Bio today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock.
Business WireIveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
PARSIPPANY, N.J., November 17, 2022--Iveric Bio announced that the U.S. FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura).
Business WireIveric Bio to Present at Upcoming Investor Conferences
PARSIPPANY, N.J., November 04, 2022--Iveric Bio announced that members of the management team will participate in fireside chats at the three investor conferences in November.
Motley FoolIVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
Representing IVERIC Bio today are Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Keith Westby, chief operating officer; David Carroll, chief financial officer; Dr. Dhaval Desai, chief development officer; Chris Simms, chief commercial officer; and Tony Gibney, chief business and strategy officer. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Business WireIveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
PARSIPPANY, N.J., November 03, 2022--IVERIC bio, Inc. announced that it has submitted to the U.S. FDA the first part of its NDA for rolling review of avacincaptad pegol.
Business WireIveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J., November 03, 2022--Iveric Bio announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update.